Trial reportJournal of pain research2026
Effects of Oxycodone versus Sufentanil-Based Intravenous Patient-Controlled Multimodal Analgesia on Early Gastrointestinal Recovery and Pain After Laparoscopic Colorectal Cancer Surgery: A Randomized Double-Blind Trial.
Trial report in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oliceridine versus Sufentanil for Postoperative Intravenous Analgesia in Patients Undergoing Abdominal Surgery in the AICU: A Double-Blind Non-Inferiority Trial.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Oxycodone is a dual μ/κ-opioid receptor agonist effective in managing both somatic and visceral pain. We compared the effect of oxycodone-based versus sufentanil-based multimodal regimens on early gastrointestinal recovery and pain control following laparoscopic colorectal cancer surgery. Methods: In this single-center, prospective, randomized, double-blind trial, 76 patients undergoing elective laparoscopic colorectal cancer surgery were allocated to the oxycodone group (Group O) or the sufentanil group (Group S). Both groups received standardized multimodal analgesia with preoperative TAP block, postoperative PCIA, and flurbiprofen axetil for rescue. The primary endpoint was time to first flatus; secondary outcomes included other recovery indicators, pain and sedation scores, opioid and PCIA use, adverse effects, PACU stay, and hospital length of stay. Results: Group O shortened time to first flatus (43.7±7.9 h vs 48.4±8.7 h, mean difference -4.8 h; 95% CI -8.6 to -1.0; P = 0.015) and time to ambulation (47.3±5.1 h vs 50.0±3.8 h, mean difference -2.7 h; 95% CI -4.8 to -0.7; P = 0.010). Group O reduced PCIA demands (median 0 vs 2), rescue analgesia (7.9% vs 26.3%), PONV (7.9% vs 31.6%), PACU stay (median 55 vs 60 min), and remifentanil use (2.8±0.4 vs 3.1±0.5 mg) (all P < 0.05). Postoperative sedation at 4 h was better in group O. Visceral pain scores at 12 h and 48 h were lower with oxycodone, whereas incisional pain and solid-food tolerance did not differ; length of stay was similar. Conclusion: Oxycodone-based multimodal analgesia was associated with improved early gastrointestinal recovery indicators, better visceral pain control, and fewer opioid-related adverse effects than the sufentanil-based regimen, but did not reduce hospital length of stay. Trial Registration: Chinese Clinical Trial Registry (ChiCTR2500100676).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.